Sanofi India Limited (SIL) has announced significant changes in its top management, with the appointment of Deepak Arora as the new Managing Director and the stepping down of Rachid Ayari from his interim role.

New Leadership at the Helm

The Board of Directors of Sanofi India, upon the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Deepak Arora as an Additional Director and Managing Director of the company. This appointment, effective from October 27, 2025, is subject to shareholder and Central Government approval. Arora's term as Managing Director is set for three years.

Deepak Arora: A Seasoned Pharmaceutical Executive

Deepak Arora brings over three decades of pharmaceutical and healthcare experience to his new role at Sanofi India. His career spans across various geographies including North America, Europe, Middle East, and Africa, where he has held leadership positions in commercial, sales, marketing, and general management roles.

Key Responsibilities

In his new position, Arora will be tasked with:

• Defining and driving the strategic vision for Sanofi in India
• Spearheading strategic priorities to boost innovation and agility
• Fostering operational excellence across all functions
• Championing the company's Diversity, Equity, and Inclusion culture

Management Transition

Simultaneously, Rachid Ayari has stepped down from his position as Interim Managing Director, effective October 26, 2025. Ayari, who was appointed to the interim role on July 21, 2025, for a six-month term or until a permanent Managing Director was appointed, will continue to serve as Whole-time Director and Chief Financial Officer of Sanofi India.

Board Authorization

The Board has also authorized Deepak Arora to determine the materiality of events and make stock exchange disclosures, alongside other Key Managerial Personnel.

Leadership's Perspective

Aditya Narayan, Chairman of the Board at Sanofi India Limited, expressed confidence in the new appointment, stating, "We are confident that under his leadership, Sanofi will continue to thrive and innovate. We extend our wholehearted support and best wishes as he embarks on this significant journey."

This management change marks a new chapter for Sanofi India as it continues its mission to promote health and chase the miracles of science to improve people's lives across the entire health spectrum in India.

Sanofi India Limited (SIL), a prominent player in the pharmaceutical industry, has announced significant changes in its leadership team, specifically in the role of Company Secretary and Compliance Officer.

Resignation of Arjun Thakkar

Mr. Arjun Thakkar, the current Company Secretary and Compliance Officer of Sanofi India Limited, has tendered his resignation effective September 30, 2025. Thakkar's decision to step down comes as he pursues a new career opportunity within the Sanofi Group, specifically in the Ethics & Business Integrity department.

The company has expressed its appreciation for Thakkar's contributions during his tenure. With his departure, Thakkar will also cease to be a Key Managerial Personnel and Senior Management Personnel of the company.

Appointment of Haresh Vala

In light of this transition, the Board of Directors of Sanofi India Limited, upon recommendation from the Nomination and Remuneration Committee, has approved the appointment of Mr. Haresh Vala as the new Company Secretary and Compliance Officer. Vala's appointment will be effective from October 1, 2025.

About Haresh Vala

Mr. Haresh Vala brings a wealth of experience to his new role at Sanofi India Limited:

• Professional Qualifications: Associate Member of the Institute of Company Secretaries of India
• Experience: Over two decades in corporate secretarial and compliance functions across diverse industries
• Education: Holds degrees in Law and Commerce from the University of Mumbai
• Expertise: Deep knowledge in corporate governance, regulatory compliance, investor relations, SEBI regulations, and Companies Act compliances
• Key Skills: Experienced in entity formation, capital structuring, fund-raising, dividend distribution, related party transactions, and compliance with LODR regulations

Vala's appointment is expected to strengthen Sanofi India's corporate governance framework and ensure compliance with regulatory requirements.

Additional Responsibilities

The Board has also authorized Mr. Haresh Vala to determine the materiality of events or information and make disclosures to the Stock Exchanges, in addition to other authorized Key Managerial Personnel. This responsibility is in line with Regulation 30(5) of the SEBI Listing Regulations.

Board Meeting Details

The decision regarding these leadership changes was made during a Board of Directors meeting held on September 25, 2025. The meeting commenced at 4:15 p.m. and concluded at 4:45 p.m.

These leadership changes at Sanofi India Limited reflect the company's commitment to maintaining strong corporate governance and ensuring smooth transitions in key roles. As the pharmaceutical industry continues to evolve, such strategic appointments are crucial for navigating regulatory landscapes and driving organizational growth.